• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Perioperative Antiplatelet Bridging With Cangrelor: A Cohort Study and Narrative Review
CONCLUSION AND RELEVANCE: This study suggests that cangrelor bridging may be a reasonable alternative to holding oral P2Y12 inhibitors in patients requiring interruption of antiplatelet therapy for an urgent surgery/invasive procedure.PMID:36004393 | DOI:10.1177/10600280221120310
Source: The Annals of Pharmacotherapy - August 25, 2022 Category: Drugs & Pharmacology Authors: Alok Salgia Chelsea K Krueger Michael A Gillette Source Type: research

Effectiveness and Safety of Enoxaparin Versus Unfractionated Heparin as Thromboprophylaxis in Hospitalized COVID-19 Patients: Real-World Evidence
CONCLUSION AND RELEVANCE: When compared with UFH, enoxaparin was associated with a significant reduction in thrombotic events or mortality among COVID-19 patients. The results need confirmation from randomized controlled trials.PMID:35942505 | DOI:10.1177/10600280221115299
Source: The Annals of Pharmacotherapy - August 9, 2022 Category: Drugs & Pharmacology Authors: Lina H AlLehaibi Mukhtar Alomar Abdulaziz Almulhim Sarah Al-Makki Nazar R Alrwaili Shahad Al-Bassam Semat Alsultan Jenan Al Saeed Mohammad Alsheef Ivo Abraham Ahmad Alamer Source Type: research

A Review of Direct Oral Anticoagulants in Patients With Stage 5 or End-Stage Kidney Disease
CONCLUSIONS: If OACs for stroke prevention with AF are deemed necessary, apixaban or rivaroxaban can be considered. DOACs cannot currently be recommended over warfarin in patients with CKD-5 or ESKD and VTE.PMID:34459281 | DOI:10.1177/10600280211040093
Source: The Annals of Pharmacotherapy - August 30, 2021 Category: Drugs & Pharmacology Authors: Jessica A Starr Nathan A Pinner Melanie Mannis Mary Katherine Stuart Source Type: research

The Impact of Body Weight and Renal Function on the Risk of Bleeding With Direct Oral Anticoagulants in Atrial Fibrillation
CONCLUSION AND RELEVANCE: This study demonstrates an association between higher baseline SCr, elevated HASBLED score, and lower weight, with an increased risk of bleeding in patients with NVAF or AFL receiving a DOAC. These findings add to prescribing considerations when initiating DOACs. Closer monitoring is advised for patients with significant renal dysfunction and/or low body weight, even with renal dose adjustments.PMID:33601914 | DOI:10.1177/1060028021995201
Source: The Annals of Pharmacotherapy - February 19, 2021 Category: Drugs & Pharmacology Authors: Hannah Whittemore Andrew K Posen Erika L Hellenbart Vicki Groo Eric Wenzler Jessica J Tilton Source Type: research

The Impact of Body Weight and Renal Function on the Risk of Bleeding With Direct Oral Anticoagulants in Atrial Fibrillation.
CONCLUSION AND RELEVANCE: This study demonstrates an association between higher baseline SCr, elevated HASBLED score, and lower weight, with an increased risk of bleeding in patients with NVAF or AFL receiving a DOAC. These findings add to prescribing considerations when initiating DOACs. Closer monitoring is advised for patients with significant renal dysfunction and/or low body weight, even with renal dose adjustments. PMID: 33601914 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - February 19, 2021 Category: Drugs & Pharmacology Authors: Whittemore H, Posen AK, Hellenbart EL, Groo V, Wenzler E, Tilton JJ Tags: Ann Pharmacother Source Type: research

Direct Oral Anticoagulants Versus Warfarin in the Treatment of Left Ventricular Thrombus.
CONCLUSION AND RELEVANCE: Our data suggest that DOACs may be reasonable alternatives for treatment of LV thrombus. When added to the totality of available studies, this study demonstrates that the effectiveness of DOACs in LV thrombus remains uncertain. Randomized clinical trials are needed. PMID: 33191781 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - November 15, 2020 Category: Drugs & Pharmacology Authors: Willeford A, Zhu W, Stevens C, Thomas IC Tags: Ann Pharmacother Source Type: research

Validation of Bleeding Risk Prediction Scores for Patients With Major Bleeding on Direct Oral Anticoagulants.
Conclusion and Relevance: The HAS-BLED, HEMORR2HAGES, RIETE, and CHEST scores were found to have sufficient diagnostic accuracy for predicting risk of major bleeding in our study population; however, no score was identified as having an AUC greater than 0.7. Caution may be considered when utilizing these scores for patients on DOACs. PMID: 32517484 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - June 8, 2020 Category: Drugs & Pharmacology Authors: Tchen S, Ryba N, Patel V, Cavanaugh J, Sullivan JB Tags: Ann Pharmacother Source Type: research

The Tasmanian Atrial Fibrillation Study (TAFS): Differences in Stroke Prevention According to Sex.
Conclusion and Relevance: Female patients with a high stroke risk were less likely to receive guideline-recommended treatment. This study provides new information on prescribing trends within the Australian setting and highlights the opportunity to improve the management of female patients with AF and 1 or more additional stroke risk factors. PMID: 32019321 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - February 3, 2020 Category: Drugs & Pharmacology Authors: Pilcher SM, Alamneh EA, Chalmers L, Bereznicki LR Tags: Ann Pharmacother Source Type: research

Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
Conclusion and Relevance: Although not statistically significant, rivaroxaban trended toward a lower incidence of clinical failure while demonstrating a significantly shorter LOS when compared with warfarin for VTE treatment or atrial fibrillation in morbidly obese or high-body-weight patients. PMID: 31672028 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - October 30, 2019 Category: Drugs & Pharmacology Authors: Perales IJ, San Agustin K, DeAngelo J, Campbell AM Tags: Ann Pharmacother Source Type: research

Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator.
Conclusion and Relevance: In the absence of a specific test, LMWH-calibrated anti-Xa assay could be used to determine the presence and evaluate the plasma concentration of oral anti-Xa inhibitors. However, these initial findings require confirmation using other chromogenic calibrated oral anti-Xa assays. PMID: 30378443 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - October 31, 2018 Category: Drugs & Pharmacology Authors: Billoir P, Barbay V, Joly LM, Fresel M, Chrétien MH, Le Cam Duchez V Tags: Ann Pharmacother Source Type: research

Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation.
Conclusion and Relevance: Apixaban and rivaroxaban may be considered as alternatives to warfarin for atrial fibrillation or flutter in morbidly obese patients. Dabigatran use in morbidly obese patients needs caution until further studies are conducted. PMID: 30130979 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - August 22, 2018 Category: Drugs & Pharmacology Authors: Kido K, Ngorsuraches S Tags: Ann Pharmacother Source Type: research

Clinical Management of Bleeding Risk With Antidepressants.
CONCLUSIONS: Clinicians must be aware of the risk of bleeding with SRI use, especially for patients taking NSAIDs. Patient education is prudent for those prescribed NSAIDs and SRIs concurrently. PMID: 30081645 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - August 6, 2018 Category: Drugs & Pharmacology Authors: Bixby AL, VandenBerg A, Bostwick JR Tags: Ann Pharmacother Source Type: research

Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease.
Conclusion and Relevance: Patients with advanced CKD taking apixaban had similar bleeding rates at 3 months compared with those taking warfarin. However, those who continued therapy had higher major bleeding rates with warfarin between 6 and 12 months. This study provides knowledge on the effects of a direct oral anticoagulant in a population that was excluded from all major trials. PMID: 29871510 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - June 1, 2018 Category: Drugs & Pharmacology Authors: Schafer JH, Casey AL, Dupre KA, Staubes BA Tags: Ann Pharmacother Source Type: research

Pages: 1  2  3